MOREPENLAB
Invest Now
Morepen Laboratories Share Price
₹75.61 +0.08 (0.11%)
17 Nov, 2024 10:16
Start SIP in MOREPENLAB
Start SIPPerformance
- Low
- ₹75
- High
- ₹78
- 52 Week Low
- ₹38
- 52 Week High
- ₹101
- Open Price₹76
- Previous Close₹76
- Volume5,664,888
Investment Returns
- Over 1 Month -16.7%
- Over 3 Month + 24.26%
- Over 6 Month + 59.68%
- Over 1 Year + 94.37%
Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!
Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 31.6
- PEG Ratio
- 0.2
- Market Cap Cr
- 4,143
- P/B Ratio
- 4.9
- Average True Range
- 4.21
- EPS
- 2.4
- Dividend Yield
- 0
- MACD Signal
- -0.91
- RSI
- 39.22
- MFI
- 46.84
Morepen Laboratories Financials
Morepen Laboratories Technicals
EMA & SMA
Current Price
₹75.61
+
0.08
(0.11%)
- Bullish Moving Average 5
- Bearish Moving Average 11
- 20 Day
- ₹80.75
- 50 Day
- ₹80.45
- 100 Day
- ₹74.70
- 200 Day
- ₹65.04
Resistance and Support
76.18
- R3 79.52
- R2 78.60
- R1 77.10
- S1 74.68
- S2 73.76
- S3 72.26
Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-11 | Quarterly Results | |
2024-08-12 | Quarterly Results | |
2024-05-21 | Audited Results | |
2024-01-31 | Quarterly Results | |
2023-11-02 | Quarterly Results |
Morepen Laboratories F&O
About Morepen Laboratories
- NSE Symbol
- MOREPENLAB
- BSE Symbol
- 500288
- Chairman & Managing Director
- Mr. Sushil Suri
- ISIN
- INE083A01026
Similar Stocks to Morepen Laboratories
Morepen Laboratories FAQs
Morepen Laboratories share price is ₹75 As on 17 November, 2024 | 10:02
The Market Cap of Morepen Laboratories is ₹4143.1 Cr As on 17 November, 2024 | 10:02
The P/E ratio of Morepen Laboratories is 31.6 As on 17 November, 2024 | 10:02
The PB ratio of Morepen Laboratories is 4.9 As on 17 November, 2024 | 10:02
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.